Clinical innovation for neurodegenerative diseases
نویسندگان
چکیده
Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease, are devastating diseases, with huge unmet medical needs. Although it has been estimated that the pharmaceutical industry has already spent billions of US dollars on developing a treatment for AD, the output so far has been dismal. We, like many others, hope that this long history of failures will soon be replaced by success. Whilst symptomatic treatments are valuable, especially those with clearly observable functional outcomes (e.g., l-DOPA in Parkinson’s disease), disease modification in terms of halting, slowing or preventing the evolution of neurodegenerative disorders remains the Holy Grail and no disease modifier product has yet been approved in any neurodegenerative disorder – with the possible exception of riluzole for amyotrophic lateral sclerosis. High cost, long timelines and low probability of success have led to reluctance by the pharmaceutical industry to invest in this area, despite the huge rewards that a successful treatments would reap [1]. Some companies have already opted to leave this area; others have decided to ‘reef the sail’. In contrast, publically funded efforts are growing. During the first decade of the 21st century, AD national plans were launched in a variety of different European countries. The US President signed the National AD Project Act in January 2011. The first European-wide Neurodegenerative Disease Research was launched in 2012. In 2013 the NIH total expenditure on AD research will reach an all-time high of US $529 million. A common belief is that public–private partnerships (PPPs) will generate breakthroughs in preclinical and clinical areas [2]. The Innovative Medicine Initiative (IMI) represents one such collaboration, which joins European governments and pharmaceutical companies together to speed up the development of better and safer medicines for patients. The IMI PharmaCog project was launched in 2010 and is already reporting data related to improved early preclinical and clinical experimental designs for predicting the cognitive properties of new drug candidates [101].
منابع مشابه
O19: Advances in the Treatment and Limitations of Cell Therapy in Neurodegenerative Diseases
Neurodegenerative diseases are the hereditary and sporadic diseases which are characterized by progressive neuronal loss of the nervous system and are emerging as the leading cause of death, disabilities, and a socioeconomic burden due to an increase in life expectancy. There are many neurodegenerative diseases including Alzheimer’s disease, Parkinson’s, disease, amyotrophic lateral...
متن کاملGenus Boswellia as a new candidate for neurodegenerative disorders
Neurodegenerative diseases, characterized by progressive loss of neurons, share common mechanisms such as apoptotic cell death, mitochondrial dysfunction, inflammation, and oxidative stress. Genus Boswellia is a genus in the Burseraceae family. It comprises several species traditionally used for treatment of chronic inflammatory diseases, cerebral edema, chronic pain syndrome, gastrointestinal d...
متن کاملNew Hopes and Challenges for Treatment of Neurodegenerative Disorders: Great Opportunities for Young Neuroscientists
متن کامل
Ionotropic Glutamate Receptors and their Role in Neurological Diseases
Glutamate is extensively and relatively uniformly distributed in the central nervous system (CNS) and its effects mediated by two distinct groups of receptors including Ionotropic and metabotropic glutamate receptors. Concentration of glutamate in the nervous system is much higher than in other tissues. Glutamate receptors play an important role in synaptic transmission, neural plasticity and n...
متن کاملP184: Combination of Herbal Medicine and Nanomedicine: a Novel Therapeutic Target for Neurodegenerative Diseases
Inflammation is a pathologic condition that includes a wide range of diseases namely neurodegenerative diseases. Several natural anti-inflammatory components have been identified in plant extracts used in traditional medicine for the relief of inflammation. Herbal medicine is showing difficulty in crossing the blood-brain barrier (BBB). So that the ability to pass the BBB is the main concern fo...
متن کاملReview Paper: Polyphenolic Antioxidants and Neuronal Regeneration
Many studies indicate that oxidative stress is involved in the pathophysiology of neurodegenerative diseases. Oxidative stress can induce neuronal damages, modulate intracellular signaling and ultimately leads to neuronal death by apoptosis or necrosis. To review antioxidants preventive effects on oxidative stress and neurodegenerative diseases we accumulated data from internatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2016